Risk and prognostic significance of metachronous contralateral testicular germ cell tumours

British Journal of Cancer

Volumn 107, Issue 9, 2012, Pages 1637-1643

  Schaapveld, M ^a,b   Van Den Belt Dusebout, A W ^a   Gietema, J A ^c   De Wit, R ^d   Horenblas, S ^a   Witjes, J A ^e   Hoekstra, H J ^c   Kiemeney, L A L M ^b,e   Louwman, W J ^f   Ouwens, G M ^a   Aleman, B M P ^a   Van Leeuwen, F E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Centre the Netherlands   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f The Netherlands   (Netherlands)

Author keywords

chemotherapy; contralateral testicular germ cell tumour; cumulative incidence; platinum; prognosis

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; PLATINUM; VINBLASTINE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GERM CELL TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIORITY JOURNAL; STANDARDIZED INCIDENCE RATIO;

ADULT; AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 84867896869     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.448     Document Type: Article

References (22)

1. Andreassen KE, Grotmol T, Cvancarova MS, Johannesen TB, Fosså SD (2011) Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7, 102 Norwegian patients (1953-2007). Int J Cancer 129: 2867-2874
2. Boshuizen HC, Feskens EJ (2010) Fitting additive Poisson models. Epidemiol Perspect Innov 7: 4
3. Breslow NE, Day NE. Statistical Methods in Cancer Research: Volume II-The Design and Analysis of Cohort Studies. IARC Scientific Publications: Lyon
4. Che M, Tamboli P, Ro JY, Park DS, Ro JS, Amato RJ, Ayala AG (2002) Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer 95: 1228-1233
5. Choudhury JB (2002) Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data. Stat Med 21: 1129-1144
6. Christensen TB, Daugaard G, Geertsen PF, von der Maase H (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9: 657-660
7. Dieckmann KP, Kulejewski M, Pichlmeier U, Loy V (2007) Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 51: 175-183
8. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Amer Statist Assoc 94: 496-509
9. Fosså SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, Travis LB (2005) Risk of contralateral testicular cancer: a populationbased study of 29, 515 U.S. men. J Natl Cancer Inst 97: 1056-1066
10. Gooley TA, Leisenring W, Crowley J, Storer BE (1999) Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18: 695-706
11. Greist A, Einhorn LH, Williams SD, Donohue JP, Rowland RG (1984) Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer. J Clin Oncol 2: 1025-1027
12. Hentrich M, Weber N, Bergsdorf T, Liedl B, Hartenstein R, Gerl A (2005) Management and outcome of bilateral testicular germ cell tumors: twenty-five year experience in Munich. Acta Oncol 44: 529-536
13. Kleinschmidt K, Dieckmann KP, Georgiew A, Loy V, Weissbach L (2009) Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with germ cell cancer. Oncology 77: 33-39
14. Osterlind A, Berthelsen JG, Abildgaard N, Hansen SO, Hjalgrim H, Johansen B, Munck-Hansen J, Rasmussen LH (1991) Risk of bilateral testicular germ cell cancer in Denmark: 1960-1984. J Natl Cancer Inst 83: 1391-1395
15. The Netherlands Cancer Registry: Cancer in figures (2012) Utrecht, the Netherlands, Association of Comprehensive Cancer Centres. http://www. cijfersoverkanker.nl/
16. Theodore Ch, Terrier-Lacombe MJ, Laplanche A, Benoit G, Fizazi K, Stamerra O, Wibault P (2004) Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer 90: 55-59
17. van Basten JP, Hoekstra HJ, van Driel MF, Sleijfer DT, Droste JH, Schraffordt Koops H (1997) Cisplatin-based chemotherapy changes the incidence of bilateral testicular cancer. Ann Surg Oncol 4: 342-348
18. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25: 4370-4378
19. van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R (1993) Second cancer risk following testicular cancer: a follow-up study of 1, 909 patients. J Clin Oncol 11: 415-424
20. von der Maase H, Rørth M, Walbom-Jørgensen S, Sørensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG, Skakkebaek NE (1986) Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 293: 1398-1401
21. Wanderås EH, Fosså SD, Tretli S (1997) Risk of a second germ cell tumor after treatment of a primary germ cell tumor in 2201 Norwegian male patients. Eur J Cancer 33: 244-252
22. Zwaveling A, Soebhag R (1985) Testicular tumors in the Netherlands. Cancer 55: 1612-1617